NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

醫藥品受託製造市場:2021∼2027年

Pharmaceutical Contract Manufacturing Market 2021-2027

出版商 Orion Market Research Pvt Ltd 商品編碼 1025430
出版日期 內容資訊 英文
商品交期: 2-3個工作天內
價格
醫藥品受託製造市場:2021∼2027年 Pharmaceutical Contract Manufacturing Market 2021-2027
出版日期: 2021年07月15日內容資訊: 英文
簡介

醫藥品受託製造的市場規模在預測期間內預計將以6.9%大幅度的年複合成長率擴大。致力於為整合或風險共擔業務模式提供增值服務的端到端服務提供商的存在有望推動該行業的進步。預計新產品的推出和新的給藥方式將推動外包需求。此外,隨著製藥行業的持續增長,製藥公司需要儲備新藥,但擁有探索、改進和製造產品的資源,因此對CMO的需求巨大,這些因素推動了醫藥合同製造市場的增長。

本報告提供醫藥品受託製造市場相關調查,提供市場概要,以及各類別,各類型,各產品,各類服務,各地區的趨勢,及加入此市場的主要企業簡介等資訊。

目錄

第1章 報告概要

第2章 市場概要與洞察

  • 調查範圍
  • 分析師的洞察和目前市場趨勢
  • 規則

第3章 競爭情形

  • 主要企業分析
    • 概要
    • 財務分析
    • SWOT分析
    • 最近的趨勢
  • 重要的策略分析
  • COVID-19對主要參與者的影響

第4章 市場決策要素

  • 成長要素
  • 阻礙因素
  • 市場機會

第5章 市場細分化

  • 全球醫藥品受託製造市場,各類別
    • 人為基礎的藥
    • 動物為基礎的藥
  • 全球醫藥品受託製造市場,各類型
    • 殺菌製造
    • 非殺菌製造
  • 全球醫藥品受託製造市場,各產品
    • 市售(OTC)藥
    • 有效成分(API)
    • 最終劑型
    • 其他(營養產品及包裝)
  • 全球醫藥品受託製造市場,各類服務
    • 製造服務
    • 非臨床服務
    • 研究開發

第6章 地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他
  • 其他地區

第7章 企業簡介

  • Aenova Holding GmbH
  • Ajinomoto Co., Inc.
  • Almac Group Ltd.
  • Amgen Inc.
  • Aurobindo Pharma Ltd.
  • Baxter International Inc.
  • BDR Pharmaceuticals International Pvt. Ltd.
  • BiologicsMD, Inc.
  • Boehringer Ingelheim International GmbH
  • Cadence Inc.
  • Chunghwa Chemical & Pharmaceutical Co., Ltd.
  • Ciron Drugs & Pharmaceuticals Pvt. Ltd.
  • Confab Laboratories Inc.
  • Daito Pharmaceutical Co., Ltd.
  • Eli Lilly And Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Hisamitsu Pharmaceutical Co., Inc.,
  • Ligand Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis International AG
  • Outlook Therapeutics, Inc.
  • Pfizer Inc.
  • PhytoHealth Corp.
  • Piramal Enterprises Ltd.
  • Procter & Gamble Co.
  • Radius Health Inc.
  • Sanofi S.A.
  • Tarsa Therapeutics, Inc.
  • Teva Pharmaceuticals Industries Ltd.
目錄
Product Code: OMR2023862

Full-title:Global Pharmaceutical Contract Manufacturing Market Size, Share & Trends Analysis by Category (Human-Based Drugs and Animals Based Drugs), By Type (Sterile Manufacturing and Non-Sterile Manufacturing,),  by Product (Over-The-Counter (OTC) Drugs, Active Pharmaceutical Ingredients (API), Finished Dosage Formulation and Others) and by services (Manufacturing Services, Non-Clinical Services, and Research & Development) Forecast, 2021-2027.

The pharmaceutical contract manufacturing market is anticipated to grow at a substantial CAGR of 6.9% during the forecast period. The presence of end-to-end service providers committed to providing value-added services for an integrated or risk-sharing business model is expected to drive forward progress in this industry. Furthermore, new product launches and new drug delivery methods are expected to drive demand for outsourcing. Moreover, with continued growth in the pharmaceutical sector, pharmaceutical companies need to stock their pipelines with new drugs. They do not, however, have the resources to explore, improve, and manufacture products. As a result, the demand for CMOs is significant and therefore these factors drive the growth of the pharmaceutical contract manufacturing market

The global pharmaceutical contract manufacturing market has seen positive growth during the COVID-19 pandemic as demand for vaccines, antibody therapy, antiviral vaccines, and other pharmaceutical products have increased. Many large manufacturing companies started hiring contract development and manufacturing organization due to the rise in pharmaceutical products demand during the pandemic.

The global pharmaceutical contract manufacturing market is segmented based on category, type, product and service. Based on the category the market is further classified into human-based drugs animals-based drugs. Based on type, the market is further segregated into sterile manufacturing and non-sterile manufacturing. Further based on product the market is classified into over-the-counter (OTC) drugs, active pharmaceutical ingredients (API), finished dosage formulation and others (nutritional products and packaging) and based on services the market is segmented into manufacturing services, non-clinical services, and research & development. The active pharmaceutical ingredient (API) segment held a significant market share due to factors such as the rising prevalence of chronic diseases such as cardiovascular disease and cancer, as well as advancements in active pharmaceutical ingredient (API) manufacturing.

Geographically market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America is projected to have a significant share in the pharmaceutical contract manufacturing market where generic drugs represent a massive opportunity for growth for region CMOs. Though CMOs in this region were cautious about taking risks on generics with low margins, however, as rising prices encourage more companies to enter the dermatology market, therefore CMOs benefited from high generics demand fueling the growth of the North American market.

Research Methodology

The market study of the global pharmaceutical contract manufacturing market is incorporated by extensive primary and secondary research conducted by the research team at OMR.& Secondary research has been conducted to refine the available data to break down the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Pharmaceutical Contract Manufacturing Market Research and Analysis by Category
  • Global Pharmaceutical Contract Manufacturing Market Research and Analysis by Product
  • Global Pharmaceutical Contract Manufacturing Market Research and Analysis by Type
  • Global Pharmaceutical Contract Manufacturing Market Research and Analysis by Services

The Report Covers

  • Comprehensive research methodology of the global pharmaceutical contract manufacturing market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global pharmaceutical contract manufacturing market.
  • Insights about market determinants that are stimulating the global pharmaceutical contract manufacturing market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Pharmaceutical Contract Manufacturing Industry
  • Recovery Scenario of Global Pharmaceutical Contract Manufacturing Industry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Regulations

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of COVID-19 on key players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Pharmaceutical Contract Manufacturing MarketbyCategory
    • 5.1.1. Human-Based Drugs
    • 5.1.2. Animals Based Drugs
  • 5.2. Global Pharmaceutical Contract Manufacturing Marketby Type
    • 5.2.1. Sterile Manufacturing
    • 5.2.2. Non-Sterile Manufacturing
  • 5.3. Global Pharmaceutical Contract Manufacturing Market by Product
    • 5.3.1. Over-The-Counter (OTC) Drugs
    • 5.3.2. Active Pharmaceutical Ingredients (API)
    • 5.3.3. Finished Dosage Formulation
    • 5.3.4. Others (Nutritional products and packaging)
  • 5.4. Global Pharmaceutical Contract Manufacturing Market by Services
    • 5.4.1. Manufacturing Services
    • 5.4.2. Non-Clinical Services
    • 5.4.3. Research and Development

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Aenova Holding GmbH
  • 7.2. Ajinomoto Co., Inc.
  • 7.3. Almac Group Ltd.
  • 7.4. Amgen Inc.
  • 7.5. Aurobindo Pharma Ltd.
  • 7.6. Baxter International Inc.
  • 7.7. BDR Pharmaceuticals International Pvt. Ltd.
  • 7.8. BiologicsMD, Inc.
  • 7.9. Boehringer Ingelheim International GmbH
  • 7.10. Cadence Inc.
  • 7.11. Chunghwa Chemical & Pharmaceutical Co., Ltd.
  • 7.12. Ciron Drugs & Pharmaceuticals Pvt. Ltd.
  • 7.13. Confab Laboratories Inc.
  • 7.14. Daito Pharmaceutical Co., Ltd.
  • 7.15. Eli Lilly And Co.
  • 7.16. F. Hoffmann-La Roche Ltd.
  • 7.17. GlaxoSmithKline PLC
  • 7.18. Hisamitsu Pharmaceutical Co., Inc.,
  • 7.19. Ligand Pharmaceuticals, Inc.
  • 7.20. Merck & Co., Inc.
  • 7.21. Novartis International AG
  • 7.22. Outlook Therapeutics, Inc.
  • 7.23. Pfizer Inc.
  • 7.24. PhytoHealth Corp.
  • 7.25. Piramal Enterprises Ltd.
  • 7.26. Procter & Gamble Co.
  • 7.27. Radius Health Inc.
  • 7.28. Sanofi S.A.
  • 7.29. Tarsa Therapeutics, Inc.
  • 7.30. Teva Pharmaceuticals Industries Ltd.

LIST OF TABLES

  • 1. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY CATEGORY,2020-2027 ($ MILLION)
  • 2. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING FOR HUMAN-BASED DRUGSMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 3. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING FOR ANIMALS BASED DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 4. GLOBALPHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY TYPE,2020-2027 ($ MILLION)
  • 5. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING FOR STERILE MANUFACTURING MARKET RESEARCH AND ANALYSIS BY REGION 2020-2027($ MILLION)
  • 6. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING FOR NON-STERILE MANUFACTURINGMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 7. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2020-2027 ($ MILLION)
  • 8. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING FOR OVER-THE-COUNTER (OTC) DRUGSMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING FOR ACTIVE PHARMACEUTICAL INGREDIENTS (API)MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 10. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING FOR FINISHED DOSAGE FORMULATION MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 11. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING FOR OTHERS(NUTRITIONAL PRODUCTS AND PACKAGING) MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 12. GLOBALPHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY SERVICE, 2020-2027 ($ MILLION)
  • 13. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING SERVICESMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 14. GLOBAL PHARMACEUTICAL CONTRACT NON-CLINICAL SERVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 15. GLOBAL PHARMACEUTICAL CONTRACT RESEARCH AND DEVELOPMENT SERVICESMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 16. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
  • 17. NORTH AMERICAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 18. NORTH AMERICAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY CATEGORY,2020-2027 ($ MILLION)
  • 19. NORTH AMERICAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 20. NORTH AMERICAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY PRODUCT,2020-2027 ($ MILLION)
  • 21. NORTH AMERICAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY SERVICES, 2020-2027 ($ MILLION)
  • 22. EUROPEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 23. EUROPEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY CATEGORY,2020-2027 ($ MILLION)
  • 24. EUROPEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY TYPE,2020-2027 ($ MILLION)
  • 25. EUROPEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2020-2027 ($ MILLION)
  • 26. EUROPEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY SERVICES, 2020-2027 ($ MILLION)
  • 27. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 28. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY CATEGORY,2020-2027 ($ MILLION)
  • 29. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY TYPE,2020-2027 ($ MILLION)
  • 30. 26. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2020-2027 ($ MILLION)
  • 31. 26. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY SERVICES, 2020-2027 ($ MILLION)
  • 32. REST OF THE WORLD PHARMACEUTICAL CONTRACT MANUFACTURING MARKETRESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 33. REST OF THE WORLD PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY CATEGORY,2020-2027 ($ MILLION)
  • 34. REST OF THE WORLD PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 35. REST OF THE WORLD PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2020-2027 ($ MILLION)
  • 36. REST OF THE WORLD PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY SERVICES, 2020-2027 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, 2020-2027 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET BY SEGMENT, 2020-2027 ($ MILLION)
  • 3. RECOVERY OF GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, 2020-2027 (%)
  • 4. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKETSHARE BY CATEGORY,2020 VS 2027 (%)
  • 5. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKETSHARE BY TYPE,2020 VS 2027 (%)
  • 6. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKETSHARE BYPRODUCT, 2020 VS 2027 (%)
  • 7. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE BY SERVICES, 2020 VS 2027 (%)
  • 8. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKETSHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 9. GLOBAL HUMAN-BASED DRUGSMARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 10. GLOBAL ANIMALS BASED DRUGSMARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 11. GLOBALSTERILE MANUFACTURINGMARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 12. GLOBALNON-STERILE MANUFACTURINGMARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 13. GLOBALOVER-THE-COUNTER (OTC) DRUGSMARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 14. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS (API)MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 15. GLOBAL FINISHED DOSAGE FORMULATIONMARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 16. GLOBAL OTHERS(NUTRITIONAL PRODUCTS AND PACKAGING) MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 17. GLOBAL. MANUFACTURING SERVICESMARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 18. GLOBAL NON-CLINICAL SERVICESMARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)

19. GLOBAL RESEARCH AND DEVELOPMENTMARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%) RESEARCH AND DEVELOPMENT

  • 20. US PHARMACEUTICAL CONTRACT MANUFACTURING MARKETSIZE, 2020-2027($ MILLION)
  • 21. CANADA PHARMACEUTICAL CONTRACT MANUFACTURING MARKETSIZE, 2020-2027($ MILLION)
  • 22. UK PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2020-2027($ MILLION)
  • 23. FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKETSIZE, 2020-2027($ MILLION)
  • 24. GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKETSIZE, 2020-2027($ MILLION)
  • 25. ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKETSIZE, 2020-2027($ MILLION)
  • 26. SPAIN PHARMACEUTICAL CONTRACT MANUFACTURING MARKETSIZE, 2020-2027($ MILLION)
  • 27. REST OF EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKETSIZE, 2020-2027($ MILLION)
  • 28. INDIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKETSIZE, 2020-2027($ MILLION)
  • 29. CHINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKETSIZE, 2020-2027($ MILLION)
  • 30. JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKETSIZE, 2020-2027($ MILLION)
  • 31. SOUTH KOREA PHARMACEUTICAL CONTRACT MANUFACTURING MARKETSIZE, 2020-2027($ MILLION)
  • 32. REST OF ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKETSIZE, 2020-2027($ MILLION)
  • 33. REST OF THE WORLD PHARMACEUTICAL CONTRACT MANUFACTURING MARKETSIZE, 2020-2027($ MILLION)